Walmart To Accelerate Investments In Key Areas To Support Faster Sales Growth
BENTONVILLE (dpa-AFX) - Walmart Inc. (WMT) today issued its 2021 Annual Report and filed its Proxy Statement in preparation for the company s upcoming virtual Annual Shareholders Meeting on Wednesday, June 2, 2021.
Walmart said it has made gains in recent years that it will protect, including the value for customers it offers and the lead it has built in pickup services.
The company is broadening the scope of products and services it offers to increase relevance in more customers lives, while layering in a more robust digital experience to improve engagement. And now it will accelerate investments in key areas to support faster sales growth and keep the current asset base fresh.
BUREAU VERITAS: Good start to the year with strong organic revenue growth in Q1 2021
hellenicshippingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hellenicshippingnews.com Daily Mail and Mail on Sunday newspapers.
Grupo Aeroportuario del Sureste, SAB de CV (ASR) Q1 2021 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Ipsen : Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
04/22/2021 | 01:01am EDT
Send by mail :
Message :
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021:
Q1 2021 sales summary
Highlights
Total Sales growth of 5.5% at CER, or 0.6% as reported, to €658.5m, despite impact of the pandemic
An increase in Specialty Care sales of 6.4%
1 to €611.5m, driven by the growth of Cabometyx
® (
A Consumer Healthcare sales decline of 5.4%
1 to €47.0m, reflecting the ongoing effects of COVID-19, partly offset by recovery in China
Press release content from Business Wire. The AP news staff was not involved in its creation.
Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
April 22, 2021 GMT
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021:
Q1 2021 sales summary
Highlights
Total Sales growth of 5.5% at CER, or 0.6% as reported, to €658.5m, despite impact of the pandemic
An increase in Specialty Care sales of 6.4% 1 to €611.5m, driven by the growth of Cabometyx ® (
cabozantinib ), Decapeptyl ® (
botulinum toxin type A )
A Consumer Healthcare sales decline of 5.4% 1 to €47.0m, reflecting the ongoing effects of COVID-19, partly offset by recovery in China